M
Manish A. Shah
Researcher at Cornell University
Publications - 355
Citations - 34460
Manish A. Shah is an academic researcher from Cornell University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 67, co-authored 317 publications receiving 29575 citations. Previous affiliations of Manish A. Shah include Duke University & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
Marcy E. MacDonald,Christine Ambrose,Mabel P. Duyao,Richard H. Myers,Carol Lin,Lakshmi Srinidhi,Glenn Barnes,Sherryl A.M. Taylor,Marianne James,Nicolet Groot,Heather MacFarlane,Barbara Jenkins,Mary Anne Anderson,Nancy S. Wexler,James F. Gusella,Gillian P. Bates,Sarah Baxendale,Holger Hummerich,Susan F. Kirby,Mike North,S. Youngman,Richard Mott,Günther Zehetner,Zdenek Sedlacek,Annemarie Poustka,Anna-Maria Frischauf,Hans Lehrach,Alan Buckler,Deanna M. Church,Lynn Doucette-Stamm,Michael Conlon O'Donovan,Laura Riba-Ramirez,Manish A. Shah,Vincent P. Stanton,Scott A. Strobel,Karen M. Draths,Jennifer L. Wales,Peter B. Dervan,David E. Housman,Michael R. Altherr,Rita Shiang,Leslie M. Thompson,Thomas J. Fielder,John J. Wasmuth,Danilo A. Tagle,John Valdes,Lawrence W. Elmer,Marc W. Allard,Lucio H. Castilla,Manju Swaroop,Kris Blanchard,Francis S. Collins,Russell G. Snell,Tracey Holloway,Kathleen Gillespie,Nicole A. Datson,Duncan Shaw,Peter S. Harper +57 more
TL;DR: In this article, the authors used haplotype analysis of linkage disequilibrium to spotlight a small segment of 4p16.3 as the likely location of the defect, which is expanded and unstable on HD chromosomes.
Journal Article
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
Manish A. Shah,Nicole A. Datson,Lakshmi Srinidhi,Vincent P. Stanton,Marcy E. MacDonald,Marc W. Allard,S. Youngman,Anna-Maria Frischauf,Richard Mott,KM Draths,Günther Zehetner,C. O’Donovan,Thomas J. Fielder,Bruce G. Jenkins,Manju Swaroop,Sherryl A.M. Taylor,Lynn Doucette-Stamm,Heather MacFarlane,Scott A. Strobel,H. E. McFarlane,Alan Buckler,Nicolet Groot,Holger Hummerich,Deanna M. Church,M. A. Anderson,Marianne James,Glenn Barnes,M. Christine,Francis S. Collins,Mabel P. Duyao,Peter B. Dervan,Gillian P. Bates,T Holloway,Peter S. Harper,TW Mcdonald,M North,K Blanchard,John J. Wasmuth,D. Shaw,Hans Lehrach,Danilo A. Tagle,Annemarie Poustka,David E. Housman,T. Huntington,Zdenek Sedlacek,Laura Riba,Susan F. Kirby,Carol Lin,Richard H. Myers,Leslie M. Thompson,Russell G. Snell,Michael Conlon O'Donovan,K Gillespie,Rita Shiang,Nancy S. Wexler,Christine Ambrose,J. F. Gusella,Sarah Baxendale,N. Groat,John Valdes +59 more
TL;DR: The Huntington's disease mutation involves an unstable DNA segment, similar to those described in fragile X syndrome, spino-bulbar muscular atrophy, and myotonic dystrophy, acting in the context of a novel 4p16.3 gene to produce a dominant phenotype.
Journal ArticleDOI
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Journal ArticleDOI
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
Ki Y. Chung,Jinru Shia,Nancy E. Kemeny,Manish A. Shah,Gary K. Schwartz,Archie Tse,Audrey Hamilton,Dorothy Pan,Deborah Schrag,Lawrence H. Schwartz,David S. Klimstra,Daniel Fridman,David P. Kelsen,Leonard B. Saltz +13 more
TL;DR: Colorectal cancer patients with EGFR-negative tumors have the potential to respond to cetuximab-based therapies, and selection or exclusion of patients for cetUXimab therapy on the basis of currently available EGFR IHC does not seem warranted.
Journal ArticleDOI
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu,Manish A. Shah,Eric Van Cutsem,Sun Young Rha,Akira Sawaki,Sook Ryun Park,Ho Yeong Lim,Yasuhide Yamada,Jian Wu,B. Langer,Michal Starnawski,Yoon-Koo Kang +11 more
TL;DR: The Avastin in Gastric Cancer (AVAGAST) trial as discussed by the authors evaluated the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer.